Latest News and Press Releases

Liquidia Corporation (LQDA) to report its third quarter 2024 financial results on November 13, 2024, via webcast at 8:30 a.m. ET

Liquidia Corporation (NASDAQ: LQDA), to report its third quarter 2024 financial results via webcast at 8:30 a.m. ET on Friday, November 8, 2024.

U.S. Supreme Court denied United Therapeutics’ petition to appeal rulings that found all claims of U.S. Patent No. 10,716,793 (‘793 Patent) were invalidDecisions that Liquidia does not infringe any...

Liquidia and Pharmosa announced they have amended the current exclusive licensing agreement for the development and commercialization of L606.

Liquidia will present a poster and host a medical theater at the CHEST 2024 annual meeting hosted by the American College of Chest Physicians this October.

MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare...

Liquidia Corporation announces raise of $67.5M.

Liquidia Corporation (LQDA) announced today that the company will present at two investor conferences this September.

Liquidia has filed litigation that challenges the recent decision by the FDA to grant 3-year new clinical investigation exclusivity to Tyvaso DPI.

The FDA has granted tentative approval of YUTREPIA™ (treprostinil) inhalation powder to treat adults with PAH and PH-ILD.